Three different thiazide potassium-sparing diuretic combinations were given to elderly patients for heart failure. Eighty patients received their allocated combinations for 3 years and had 6-monthly measurements of plasma potassium. A further 84 were recruited for study but 29 died within 6 months and 55 had to be withdrawn from the trial. The triamterene-containing preparation was discontinued most frequently (6/44) because of hypokalaemia (plasma potassium <3.0mmol/1); amiloride (5/44) and spironolactone (1/47). The median fail in plasma potassium over 3 years in those patients not withdrawn because of hypokalaemia was similar in each case (P>0.05) and possibly failed to reach significance because of the withdrawal rate (9%). The trend was for a greater fail in those patients taking triamterene. The spironolactone-containing preparation may be the least unsatisfactory of the three.
Introduction
Thiazide-induced hypokalaemia is well known,' but there is debate about its clinical importance.2 3 When attempting to prevent hypokalaemia a potassium supplement may prove adequate.4 A potassium-sparing drug may be preferable and has an additive diuretic effect,5'6 although none is totally satisfactory.7 -9 Thiazide potassium-sparing diuretic combinations are amongst the most widely prescribed drugs especially in the elderly. 10 The three most commonly prescribed preparations are: spironolactone 50mg + hydroflumethiazide 50mg (S/HFT-Aldactide 50); triamterene 50mg + hydrochlorothiazide 25mg (T/HCT-Dyazide) and amiloride 5mg + hydrochlorothiazide 50mg (A/HCTModuretic).
The use of potassium-sparing diuretics combined with thiazides has been studied in hypertensive patients in the short term" I -15 and by one group in the long term. '6 Chronic effects in patients with heart failure have received little attention and these three combinations have not previously been compared directly with each other. We have compared the long term effects of the above preparations on a group of elderly patients from both a clinical perspective and with reference to the effects on plasma potassium concentrations.
Patients and methods
Patients with cor pulmonale or ischaemic left ventricular failure, who received their first dose of a loop diuretic at the time of admission and required continued treatment, were considered for the study. Right or left ventricular failure was diagnosed using standard criteria. 17, 18 No patient was taking digoxin; all patients with cor pulmonale were receiving beta, agonist therapy. The recruitment period was 17 months, beginning in mid 1981. The study finished in the spring of 1986. Exclusion criteria were: age <65 years, previous diuretic therapy, steroid-dependent airways disease, diabetes mellitus or hypertension, hepatic or renal disease, serum creatinine > 130,umol/A, plasma potassium <3.5mmol/I and daily diuretic requirement in excess of bumetanide 1 mg or frusemide 40mg. Verbal consent to participate in the trial was obtained. The design had been approved by the District Ethical Committee.
On discharge from hospital the loop diuretic was changed to one of the three study combinations. Patients were randomly allocated to receive one tablet of S/HFT, two tablets of T/HCT or one tablet of A/HCT and were followed-up for 3 years. Beta-agonist therapy was continued in all patients with cor pulmonale. Potassium supplementation and dietary advice were not given. The patients' general practitioners were informed of the study and asked not to alter therapy unless in an emergency. At 36 months half the patients taking S/HFT and A/HCT had plasma potassium concentrations of 3.5mmol/l or less but 75% of those taking T/HCT were below this value (Table III) . Conversely, plasma potassium was 4.0mmol/l or more in 3 patients treated with S/HFT and in 4 each of those who took T/HCT or A/HCT. There was no significant difference at any time in plasma potassium concentration between those patients taking betaagonist therapy and those who were not.
Discussion
We have shown that median plasma potassium concentrations fell progressively in our 80 patients over 36 months of treatment. We found that S/ HFT caused least hypokalaemia, T/HCT the most and A/HCT an intermediate amount. The failure of the differences to reach statistical significance is probably due to withdrawal of patients because of severe hypokalaemia.
Because the patients were seen frequently, had their tablets counted and were questioned regarding therapy, it is improbable that any additional diuretic or potassium supplement was prescribed by a general practitioner.
The thiazide dose was equipotent because we used two tablets of T/HCT and only one of each of the other preparations.21 The quantities of potassium-retaining drugs in the combinations studied may not be precisely equivalent.14,15,22 Nevertheless our principal aim was to determine the long term effects of the three most commonly prescribed thiazide potassium-sparing diuretic combinations in patients with oedema. The median fall in plasma potassium concentration in our 80 patients (0.5mmol/l over 3 years) was very similar to that found in patients in the Medical Research Council Trial who took bendrofluazide 10mg daily.23 This suggests little benefit from the potassium-sparing component of the combinations which is contrary to the advice given in Prescribers' Journal in 1985.24 Our figure of 0.5mmol/l may be an underestimate because of the withdrawal of 12 patients whose plasma potassium fell below 3.5 mmol/l. Moderate hypokalaemia (< 3.5 mmol/l) developed in 42 out of 135 elderly patients receiving the study drugs for more than 6 months for heart failure. Severe hypokalaemia ( < 3.0 mmol/l) developed at up to 36 months after starting treatment. This conflicts with the observations of Morgan and Davidson,1 who cited short term studies except for one which lasted 2 years, but is supported by other published work.2 Dietary potassium intake in this elderly population living in a deprived inner city area may have been inadequate.
We recommend that plasma potassium should be assayed within 6 months of starting elderly patients on therapy with any of these combinations and then regularly for the duration of treatment.
The spironolactone-containing preparation appears least likely to induce hypokalaemia. Twelve patients had to be withdrawn because of hypokalaemia and because no preparation caused significantly more withdrawals than any other, a Type-II error25 may have accounted for our inability to show statistically significant differences between them. If it had been acceptable to continue treatment in all patients for 3 years it is probable that we would have shown significantly less hypokalaemia with the spironolactone-containing preparation than with the others.
